A 5-HT1 agonist was shown to improve abdominal symptom scores in patients with FD, whereas a 5-HT1A agonist, R-137696, failed to improve symptoms or visceral hypersensitivity in patients with FD. Here, HTR1A is linked to Fabry disease.